Online inquiry

IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4394MR)

This product GTTS-WQ4394MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD80&CD86 gene. The antibody can be applied in Kidney transplant rejection research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005191.4; NM_001206924.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 941; 942
UniProt ID A0N0P2; P42081
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4394MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7668MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEN3013
GTTS-WQ13767MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ9505MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA J2898A
GTTS-WQ10474MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ15539MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ1637MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-910
GTTS-WQ2497MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ15967MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ZTS-00508841
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW